GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults

Phase 2

Completed

Conditions: Tuberculosis

Interventions: Biological: GSK Biologicals' AS01B adjuvant
Biological: GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2
Biological: GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 2
Biological: GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 1
Biological: GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 3
Biological: GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 1

First Posted Date: 2008-02-22

Last Posted Date: 2018-08-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 180

Registration Number: NCT00621322

Locations: 🇵🇭
GSK Investigational Site, Manila, Philippines

A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Lung Cancer, Non-Small Cell

Interventions: Drug: pazopanib
Drug: erlotinib
Drug: pemetrexed

First Posted Date: 2008-02-21

Last Posted Date: 2017-11-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 58

Registration Number: NCT00619424

Locations: 🇮🇹
GSK Investigational Site, Orbassano (TO), Piemonte, Italy

Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: Placebo
Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted

First Posted Date: 2008-02-15

Last Posted Date: 2018-06-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 4561

Registration Number: NCT00616928

Locations: 🇨🇦
GSK Investigational Site, St-Romuald, Quebec, Canada

Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Midazolam
Drug: Rosiglitazone
Drug: Flurbiprofen
Drug: GSK376501

First Posted Date: 2008-02-14

Last Posted Date: 2017-09-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 23

Registration Number: NCT00615212

Locations: 🇺🇸
GSK Investigational Site, Buffalo, New York, United States

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Phase 2

Withdrawn

Conditions: Hormone-receptor Positive Breast Cancer

First Posted Date: 2008-02-14

Last Posted Date: 2018-01-12

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT00615524

Locations: 🇺🇸
GSK Clinical Trials Call Center, San Francisco, California, United States

Repeat Dose Study in Male Healthy Volunteer Smokers

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo
Drug: SB-656933

First Posted Date: 2008-02-14

Last Posted Date: 2017-08-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 13

Registration Number: NCT00615576

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

Phase 3

Completed

Conditions: Infections, Meningococcal

Interventions: Biological: Infanrix®
Biological: GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)
Biological: ActHIB®
Biological: GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)
Biological: Pediarix®